Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

S Rafiq, OO Yeku, HJ Jackson, TJ Purdon… - Nature …, 2018 - nature.com
The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding
tumors can be enhanced by administering the cells in combination with immune checkpoint …
被引用次数：727 相关文章

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

S Rafiq, OO Yeku, HJ Jackson, TJ Purdon… - Nature …, 2018 - go.gale.com
The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding
tumors can be enhanced by administering the cells in combination with immune checkpoint …

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.

S Rafiq, OO Yeku, HJ Jackson, TJ Purdon… - Nature …, 2018 - europepmc.org
The efficacy of CAR-T cell therapy against poorly responding tumors has been enhanced by
administering the cells in combination with immune checkpoint blockade inhibitors …

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

S Rafiq, OO Yeku, HJ Jackson… - Nature …, 2018 - pubmed.ncbi.nlm.nih.gov
The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding
tumors can be enhanced by administering the cells in combination with immune checkpoint …

[引用][C] Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

S Rafiq, OO Yeku, HJ Jackson, TJ Purdon… - Nature …, 2018 - cir.nii.ac.jp
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
[HTML] nih.gov

[HTML][HTML] Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

S Rafiq, OO Yeku, HJ Jackson, TJ Purdon… - Nature …, 2018 - ncbi.nlm.nih.gov
The efficacy of CAR-T cell therapy against poorly responding tumors has been enhanced by
administering the cells in combination with immune checkpoint blockade inhibitors …

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

S Rafiq, OO Yeku, HJ Jackson, TJ Purdon… - Nature …, 2018 - nature.com
The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding
tumors can be enhanced by administering the cells in combination with immune checkpoint …

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.

S Rafiq, OO Yeku, HJ Jackson, TJ Purdon… - Nature …, 2018 - europepmc.org
The efficacy of CAR-T cell therapy against poorly responding tumors has been enhanced by
administering the cells in combination with immune checkpoint blockade inhibitors …